EC contracts to acquire more mRNA COVID-19 vaccines
The European Commission revealed on Friday that it has agreed with Germany’s BioNTech (Nasdaq: BNTX) and its partner Pfizer (NYSE: PFE) to accelerate the delivery of their mRNA vaccine COVID-19, Comirnaty, to European Union member states, starting in a few weeks.
In the first quarter of 2022, BioNTech-Pfizer will deliver an additional 20 million vaccine doses (5 million in January, 5 million in February and 10 million in March). These doses come on top of the already scheduled 195 million doses from BioNTech-Pfizer, bringing the total number of deliveries in the first quarter to 215 million.
Last Thursday 16 December, the Commission also agreed with Moderna (Nasdaq: MRNA) on the delivery of additional doses the US company’s Spikevax (elasomeran mRNA vaccine) in the first quarter of 2022.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze